| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Research and development | 18,607 | 20,925 | 15,517* | |
| General and administrative | 10,946 | 8,937 | 2,571* | |
| Total operating expenses | 29,553 | 29,862 | 18,087 | |
| Loss from operations | -29,553 | -29,862 | -18,087* | |
| Interest income | 4,838 | 2,481 | 391* | |
| Other income | 1,213 | 149 | 198* | |
| Interest expense | - | - | 0* | |
| Total other income, net | 6,051 | 2,630 | 588* | |
| Loss before income taxes | -23,502 | -27,232 | -17,499* | |
| Federal tax at statutory rate | - | - | 3,675* | |
| Permanent differences | - | - | -55* | |
| Research and development credits | - | - | -621* | |
| Change in valuation allowance | - | - | -4,241* | |
| Income tax benefit | 0 | 0 | 0* | |
| Net loss | -23,502 | -27,232 | -17,499* | |
| Net unrealized losses on marketable securities | -371 | -584 | 15 | |
| Total other comprehensive loss | -371 | -584 | 15* | |
| Total comprehensive loss | -23,873 | -27,816 | -17,484 | |
| Basic EPS | -0.58 | -1.32 | -23.468 | |
| Diluted EPS | -0.58 | -1.32 | -23.468 | |
| Basic Average Shares | 40,436,264 | 22,704,124 | 744,991 | |
| Diluted Average Shares | 40,436,264 | 22,704,124 | 744,991 | |
Veradermics, Inc (MANE)
Veradermics, Inc (MANE)